Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?

Slides:

Advertisements

Similar presentations

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Advertisements

Evaluation of ReeKross balloon catheter in treating iliofemoral artery chronic total occlusions Xinwu Lu Vascular Center of Shanghai Jiaotong University.

Drug Coated Balloons for PAD William B. Newton III, MD Assistant Professor of Surgery Department of Vascular and Endovascular Surgery.

A Comparison of the Moxy™ Drug Coated Balloon Catheter vs. Standard PTA for Femoropopliteal Disease NCT# MONTH RESULTS OF THE LEVANT I TRIAL.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Can Drug-Coated Balloons Work in Synergy with Stent Grafts?

DCB Potential Beyond the Selected SFA Lesions Types Studied in Trials to Date What We Know About the ‘Real World’ Krishna Rocha-Singh, MD Chief Scientific.

Heavily calcified SFA lesions do not avoid the use of 4 F systems

Fem-Pop Stenting: Is ZILVER PTX DES The “De Facto” Stent to Deploy?

Medical Director of the Vascular Center

OCT-Guided PCI What needs to be done to establish criteria?

Drug-Coated Balloons in Peripheral Artery Disease

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Trends in Coronary Procedures per 1000 Medicare Beneficiaries

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Renal Denervation Two Late-Breaking Clinical Trials.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Panelists. Panelists Drug-Coated Balloon for PAD.

Goals of Therapy for Patients With UC

Thrombosis, Cancer, and NOACs

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

The Safety and Efficacy of Full vs

Metastatic Renal Cell Carcinoma

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

PCP Perspectives Clinical Considerations in Hyperkalemia

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

New Treatments for CTEPH

Selecting NOACs for High-Risk Patients

Managing CINV and Cachexia

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

American College of Cardiology Presented by Dr. Stephan Windecker

Efficacy and Safety of Edoxaban in Patients With AF and HF

Selected Highlights of the Latest Advances in PAH

Antithrombotic Protection in CAD and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

Understanding PAD.

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

A Better Solution For Cancer Patients With VTE?

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Drug-Coated Balloons:

Oral Anticoagulation in AF

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.

Aspirin and Cardioprevention in 2018

Drug-Coated Balloon Angioplasty Confers No Advantage in the Treatment of Femoropopliteal Disease When Stenting Is Required Brian Tiu, MD, Michael Shih,

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Updates in Anticoagulation: Key Sessions at ESC 2017

Iron Deficiency in Heart Failure

Preparing for Checkpoint Inhibitors in Breast Cancer

Reducing Risk for CV Outcomes

Treatment of limb-threatening ischemia with percutaneous intentional extraluminal recanalization: a preliminary evaluation Gerald S Treiman, MD, John.

Division of Endovascular Interventions

Third-Generation EGFR TKIs

Efficacy of stent-supported subintimal angioplasty in the treatment of long iliac artery occlusions Young-Guk Ko, MD, Sanghoon Shin, MD, Kwang Joon Kim,

What's New in Oral Combination Therapy for Type 2 Diabetes?

My PAH Patient.

Panelists. Panelists Drug-Coated Balloon for PAD.

Antithrombotic Therapy in AF Patients Undergoing PCI

Translating Data From Trial to Practice

Presentation transcript:

Can Drug-Coated Balloons Be a Solution for Complex Peripheral Lesions?

Case Study

Case Study (cont)

Treatment Decisions

Total IN.PACT Pooled Analysis Initiative

Total IN.PACT Pooled Analysis Initiative (cont)

Total IN.PACT Pooled Analysis Initiative - Primary Endpoints

All Subjects Baseline Lesion/Procedural Characteristics

Primary Efficacy Outcome

Total IN.PACT Imaging (Patency) Analysis

Imaging Cohort Baseline Lesion/Procedural Characteristics

Total IN.PACT Imaging Cohort

Total IN.PACT Imaging Subgroup Analysis

Total IN.PACT Propensity-Matched Analysis

Total IN.PACT Propensity-Matched Cohort

Total IN.PACT Summary

Patient Case: CO2 Aortoiliac Arteriogram Subintimal SFA Passage, Wire Loop Advanced to Diseased Re-Entry Site

Patient Case

Patient Case: Peroneal Runoff, Long Segment Predilation, Long Segment IN.PACT Admiral DCB

Patient Case Spot Stent of Dissection at Re-Entry Site

Patient Case Spot Stent of Dissection at Proximal SFA

IN.PACT SFA Trial

IN.PACT SFA Trial Endpoints

IN.PACT SFA Trial Baselines Characteristics

IN.PACT SFA Trial

The Impact of IN.PACT

Abbreviations